Stone Ridge Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Stone Ridge Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,700	Closed	-$237K	–	52
2016 Q1	$237K	Hold	1,700	–	–	1.44%	30
2015 Q4	$324K	Hold	1,700	–	–	1.1%	20
2015 Q3	$266K	Hold	1,700	–	–	1.05%	32
2015 Q2	$307K	Hold	1,700	–	–	0.71%	34
2015 Q1	$295K	Hold	1,700	–	–	0.74%	37
2014 Q4	$315K	Buy	+1,700	New	+$315K	0.66%	27

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stone Ridge Asset Management's ALXN Position: Q2 2016 in Review

Stone Ridge Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 1,700 shares — an estimated $237K sold.

Stone Ridge Asset Management first reported a position in ALXN in Q4 2014 and held it in 6 quarters. The position peaked at $324K in Q4 2015. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

Stone Ridge Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Stone Ridge Asset Management sold 1,700 Alexion Pharmaceuticals shares in Q2 2016, an estimated $237K.
Stone Ridge Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Stone Ridge Asset Management's Alexion Pharmaceuticals position peaked at $324K in Q4 2015.
533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Stone Ridge Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.